158 related articles for article (PubMed ID: 12468958)
1. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules.
Edsbäcker S; Larsson P; Wollmer P
Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1357-62. PubMed ID: 12468958
[TBL] [Abstract][Full Text] [Related]
2. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules.
Edsbäcker S; Bengtsson B; Larsson P; Lundin P; Nilsson A; Ulmius J; Wollmer P
Aliment Pharmacol Ther; 2003 Feb; 17(4):525-36. PubMed ID: 12622761
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation.
Brunner M; Ziegler S; Di Stefano AF; Dehghanyar P; Kletter K; Tschurlovits M; Villa R; Bozzella R; Celasco G; Moro L; Rusca A; Dudczak R; Müller M
Br J Clin Pharmacol; 2006 Jan; 61(1):31-8. PubMed ID: 16390349
[TBL] [Abstract][Full Text] [Related]
4. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease.
Lundin P; Naber T; Nilsson M; Edsbäcker S
Aliment Pharmacol Ther; 2001 Jan; 15(1):45-51. PubMed ID: 11136277
[TBL] [Abstract][Full Text] [Related]
5. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations.
Seidegård J; Randvall G; Nyberg L; Borgå O
Pharmazie; 2009 Jul; 64(7):461-5. PubMed ID: 19694184
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
Edsbäcker S; Andersson T
Clin Pharmacokinet; 2004; 43(12):803-21. PubMed ID: 15355126
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole.
Edsbäcker S; Larsson P; Bergstrand M
Aliment Pharmacol Ther; 2003 Feb; 17(3):403-8. PubMed ID: 12562453
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
Lundin PD; Edsbäcker S; Bergstrand M; Ejderhamn J; Linander H; Högberg L; Persson T; Escher JC; Lindquist B
Aliment Pharmacol Ther; 2003 Jan; 17(1):85-92. PubMed ID: 12492736
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers.
Nicholls A; Harris-Collazo R; Huang M; Hardiman Y; Jones R; Moro L
J Int Med Res; 2013 Apr; 41(2):386-94. PubMed ID: 23569029
[TBL] [Abstract][Full Text] [Related]
10. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
[TBL] [Abstract][Full Text] [Related]
11. A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals.
Song IH; Finkelman RD; Lan L
Drugs R D; 2020 Dec; 20(4):359-367. PubMed ID: 33057953
[TBL] [Abstract][Full Text] [Related]
12. [Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?].
Nos Mateu P
Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():16-21. PubMed ID: 19087859
[No Abstract] [Full Text] [Related]
13. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
15. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H
Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
[TBL] [Abstract][Full Text] [Related]
16. Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler.
Kirkpatrick C; Buck H; Ellis S
J Aerosol Med; 2003; 16(1):31-6. PubMed ID: 12737682
[TBL] [Abstract][Full Text] [Related]
17. Enteric-Coated Capsules Providing Reliable Site-Specific Drug Delivery to the Distal Ileum.
Grimm M; Großmann L; Senekowitsch S; Rump A; Polli JE; Dressman J; Weitschies W
Mol Pharm; 2024 Jun; 21(6):2828-2837. PubMed ID: 38723178
[TBL] [Abstract][Full Text] [Related]
18. A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone.
Edsbäcker S; Nilsson M; Larsson P
Aliment Pharmacol Ther; 1999 Feb; 13(2):219-24. PubMed ID: 10102953
[TBL] [Abstract][Full Text] [Related]
19. The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation.
Skinhøj A; Bechgaard H; Chasseaud LF; Brodie RR; Sharman JM; Taylor T; Hunter JO
Int J Clin Pharmacol Ther Toxicol; 1984 Oct; 22(10):557-61. PubMed ID: 6511132
[TBL] [Abstract][Full Text] [Related]
20. [Study on in vitro release empirical method and the release mechanism of budesonide colonic localization tablet].
Liu H; Pan WS; Nie SF; Yang XG; Yan TX
Yao Xue Xue Bao; 2008 Nov; 43(11):1147-51. PubMed ID: 19239036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
